Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pinguecula ligation with or without subconjunctival bevacizumab
IRCT20240702062306N1Phase 3Completed
- Sponsor
- Mazandaran University of Medical Sciences
- Start
- Nov 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of bevacizumab in pinguecula (2 arms), sponsored by Mazandaran University of Medical Sciences. Primary endpoints: Size, Photophobia and 1 more. Started Nov 2020; status: completed.
02
Drugs
bevacizumab
03
Conditions
pinguecula
Beyond the preview
Go deeper on IRCT20240702062306N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20240702062306N1.